Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2008

View Archived Issues

Mutations behind Duane's retraction syndrome identified

Background data on CR-845 presented during recent World Congress on Pain

Preliminary phase II results show pain relief with XEN-2127 in oncology patients

Terlipressin benefits patients awaiting liver transplant with renal failure, hyponatremia

ALK-Abello reports positive results from phase II/III of allergy vaccine against dust mites

Rosetta enters collaboration with NIH to identify microRNAs involved in HIV viral replication

Pipex acquires AT-001 for rheumatoid arthritis

DelSite files IND with the FDA for phase I safety and immunogenicity study of GelVac

New therapeutic agents for obesity described in recent patents

Recent patent literature discloses new anticancer agents

New treatment options for osteoporosis disclosed in recent Novartis patent

V-2006 development for Parkinson's disease advances

Biovex receives regulatory clearance to begin studies with ImmunoVEX-HSV2

PolyMedix commences dosing in phase I novel systemic antibiotic trial

Repros reports no tumors in completed Proellex animal carcinogenicity study

Vidaza receives expanded FDA approval in high-risk MDS patients

Metvix prevents precancerous lesions in transplant patients

Ardea Biosciences commences phase I trials for gout candidate RDEA-594

Cymbalta approved in Europe for the treatment of generalized anxiety disorder

FDA fast tracks ferumoxytol for vascular-enhanced magnetic resonance imaging

Phase III trial commences for Nexavar as adjuvant therapy in liver cancer

Auris Medical reports results of phase I/II AM-101 trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...